We see more and more pharmaceuticals industries developing digital “add-on” to classical drugs. In this article Otsuka America explain why it’s important to think “beyond medication” to help patient in everyday life.
CT-152 is a software application that will use cognitive therapy principles to treat patients either independently or in conjunction with prescribed pharmacotherapies. It is aimed the product will fall under the Food and Drug Administration’s regulatory framework and be classed as Software as a Medical Device (SaMD).
Source: Digital therapy for depression to de developed through pharma collaboration – EPM Magazine
